In the past many chronic wounds would last years if not decades. This technology has proved a very important addition in our armamentarium and proved very efficacious, even in intractable settings and wounds.
St. Petersburg FL (PRWEB) October 22, 2009
The Advanced Wound Management Division of Smith & Nephew plc (LSE: SN; NYSE: SNN) announced that the Ernest C. Manning Awards Foundation recognized Dr. Robert Burrell, inventor of ACTICOAT™ Silver-Coated Antimicrobial Barrier Dressings for his pioneering use of nanocrystalline silver to create effective, fast-acting antimicrobial barrier protection in a range of dressing types and sizes that may help prevent life threatening infections and facilitate the natural healing process.
"Because of Dr. Burrell's innovative thinking and inventive spirit, millions of patients with infected wounds have experienced the benefits of ACTICOAT, Silver-Coated Antimicrobial Barrier Dressings. We want to recognize and congratulate Dr. Burrell. He exemplifies the Smith & Nephew brand and company vision, 'Helping people regain their lives through Performance, Innovation, and Trust," said Roger Teasdale, President, Advanced Wound Management, Smith & Nephew.
"ACTICOAT Silver-Coated Antimicrobial Barrier Dressings are trusted by surgeons, nurses and other clinicians in burn units, diabetic foot clinics, and wound clinics around the world to kill pathogens, and help wounds progress towards closure," said Tom Dugan, North American President, Smith & Nephew Advanced Wound Management.
First introduced in the US in 1998, ACTICOAT has gained the respect of physicians world wide. It is a unique antimicrobial barrier dressing that offers exceptional performance, efficacy and protection:
- Broad Spectrum: ACTICOAT is proven bactericidal against 150+ pathogens including MRSA, VRE and Pseudomonas aeruginosa (1,2)
- Rapid Onset: ACTICOAT kills bacteria in 30 minutes (3,4)
- Sustained bactericidal effects: The antimicrobial barrier of ACTICOAT remains effective for up to three to 7 days(5), reducing cost and the need for painful or inconvenient dressing changes(6).
In August, 2009, Smith & Nephew introduced ACTICOAT Flex 3 and Flex 7. Combining the flexibility of a polyester mesh substrate with the power of nanocrystalline silver technology, the ACTICOAT Flex line provides enhanced conformability on awkward anatomical areas such as the face and hands, and breakthrough stretch properties to improve patient comfort during wear.
"Acticoat™, in my opinion, is one of the biggest breakthroughs in wound care in the last 40 years," says Dr. Mayer Tenenhaus, an Associate Professor of Plastic and Reconstructive Surgery at the University of California at San Diego Medical Center, where the burn unit team treats about 300 burn patients every year.
Tenenhaus lists improved care and reduced costs as two benefits to the dressings. "Then there are the intangibles of giving people their dignity back," adds Tenenhaus. "In the past many chronic wounds would last years if not decades. This technology has proved a very important addition in our armamentarium and proved very efficacious, even in intractable settings and wounds."
Dr. Burrell received the EnCana Principal Award from the Ernest C. Manning Awards Foundation, which was established in 1980 to support and promote Canadian innovators. Dr. Burrell is the lead inventor on more than 290 patents and patents pending related to ACTICOAT technology, having begun his work on the antimicrobial properties of silver in the early 1990s. A microbiologist by training, Dr. Burrell has become expert in burn and chronic wound healing. He is presently Canada Research Chair in Nanostructured Biomaterials and a professor with the Faculties of Engineering and Medicine & Dentistry at the University of Alberta.
For more information about ACTICOAT, please visit http://www.ACTICOAT.com, where case studies and references, as well as product and other information is available. For more information regarding Smith & Nephew, please visit http://www.smith-nephew.com.
1. In vitro study data on file: Scientific Background #0109003 and #0107010
2. Wright J.B., Lam K., Hansen D., Burrell R.E., Comparative evaluation of the antimicrobial activity of ACTICOAT antimicrobial barrier dressing. J Burn Care Rehabil, 1999;20;195-200
3. Smith & Nephew Wound Management. Data on file report - 0810018
4. Smith & Nephew Wound Management. Data on file report - 0810014
5. Smith & Nephew Wound Management Data on file report - 0810012. October 2008
6. Cuttle L. et al. A retrospective cohort study of ACTICOAT versus Silvazine in a pediatric population. Burns 2007;33(6); 701-7
Steve DiMattia +1 (646) 201 5445
EVC Group, Inc.
Investors and Analysts
Liz Hewitt +44 (0)20 7401 7646
Group Director Corporate Affairs
Smith & Nephew
President, Smith & Nephew Advanced Wound Care, North America
About Smith & Nephew
Smith & Nephew is a global medical technology business, specializing in Orthopeadics, including Reconstruction, Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopeadics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were nearly $3.8 billion.
This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
# # #